Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") on behalf of purchasers of Organon securities ...

Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") on behalf of purchasers of Organon securities ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of Organon & Co. (NYSE: OGN) securities between October 31, 2024 ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations ...

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, ...

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, ...

The company’s most notable recent move was the acquisition of Dermavant, a dermatology-focused firm, which has expanded Organon’s portfolio in the U.S. market. This acquisition aligns with the company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal's closure, Organon has added Dermavant’s VTAMA (tapinarof ...

Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms.

BASEL, Switzerland - Organon (NYSE: OGN), a global healthcare company, has announced the completion of its acquisition of Dermavant Sciences Ltd., a dermatological company, from Roivant (NASDAQ: ROIV) ...

BASEL, Switzerland - Organon (NYSE: OGN), a global healthcare company, has announced the completion of its acquisition of Dermavant Sciences Ltd., a dermatological company, from Roivant (NASDAQ ...

Organon will pay Dermavant up to $1.2 billion for the acquisition. Organon and Dermavant have entered a definitive agreement in which Organon will acquire Dermavant, according to a press release.